Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,088 across all filing types
Latest filing 2024-02-05 Earnings Release
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
2023年度业绩快报
Earnings Release Classification · 95% confidence The document is titled '2023 年度业绩快报' which translates to '2023 Annual Performance Express Report' or 'Earnings Quick Report'. It contains preliminary financial data for the year 2023, including revenue, profit, and other financial metrics. The text explicitly states that the data is preliminary, unaudited, and subject to change in the forthcoming annual report. The document length is 1491 characters, which is relatively short and consistent with a brief earnings release rather than a full annual report. It also includes a caution about investment risk due to the preliminary nature of the data. There is no indication that this is a full audited annual report (10-K), nor is it an announcement of the report's publication (RPA). The content matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only.
2024-02-05 Chinese
关于取得发明专利证书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (620 characters) from a company about obtaining an invention patent certificate issued by the Chinese National Intellectual Property Administration. It includes details about the patent and its impact on the company. There is no financial data, no mention of financial results, no regulatory filings related to financial performance, no meeting materials, no voting results, no management changes, no legal proceedings, no capital changes, and no other financial or governance report content. The document is an official announcement about intellectual property rights, which does not fit into any of the specific financial or corporate filing categories. Given the content and length, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2024-01-23 Chinese
关于取得发明专利证书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (601 characters) about the company obtaining an invention patent certificate. It includes details about the patent and its impact on the company. There is no financial data, no mention of financial results, no regulatory certifications, or meeting materials. It is not a report or a financial filing but a regulatory announcement about intellectual property. Given the content and length, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2024-01-02 Chinese
关于披露简式权益变动报告书的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a detailed announcement about the change in shareholding percentage of a significant shareholder (Xiamen Keying Investment Partnership) in the company Xiamen Aide Bio-Pharmaceutical Technology Co., Ltd. It provides a timeline of shareholding changes, including stock incentives, share repurchases, and block trades, resulting in the shareholder's stake falling below 5%. The document references compliance with securities laws and disclosure obligations. It is not a financial report, earnings release, or management discussion. It is a notification of a major shareholding change, specifically about crossing the 5% ownership threshold. The document length is under 5,000 characters and contains detailed shareholding data, consistent with a Major Shareholding Notification filing.
2023-11-27 Chinese
简式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the changes in shareholding of a significant shareholder (厦门科英投资合伙企业) in the company 厦门艾德生物医药科技股份有限公司. The document includes detailed information about the shareholder's equity changes, shareholding percentages before and after the changes, the purpose of the changes, and compliance with relevant securities laws and regulations. It also references the reduction of shareholding below 5%, which is a threshold for major shareholding notifications. The document is not an annual report, earnings release, or any other financial report but a formal notification of changes in significant share ownership. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length (8504 characters) and detailed content confirm it is the report itself, not just an announcement or certification.
2023-11-27 Chinese
关于2023年限制性股票激励计划首次授予限制性股票（回购部分）授予登记完成的公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from a company regarding the completion of registration for the first grant of restricted shares under a 2023 restricted stock incentive plan, including details about the number of shares, grant price, approval procedures, performance targets, and share repurchase information. It is a formal disclosure about a stock incentive plan and related share issuance and repurchase activities. The content focuses on the grant of restricted stock, share repurchase, and related approvals, which aligns with announcements about share issues or capital changes. It is not a full financial report, earnings release, or management discussion, nor is it a proxy or voting result announcement. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA). The document length and detail confirm it is not a mere announcement of a report (RPA) or a regulatory filing (RNS).
2023-11-24 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.